<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35772643</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2212-8778</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular metabolism</Title><ISOAbbreviation>Mol Metab</ISOAbbreviation></Journal><ArticleTitle>Pharmacological inhibition of ALCAT1 mitigates amyotrophic lateral sclerosis by attenuating SOD1 protein aggregation.</ArticleTitle><Pagination><StartPage>101536</StartPage><MedlinePgn>101536</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101536</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molmet.2022.101536</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2212-8778(22)00105-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Mutations in the copper-zinc superoxide dismutase (SOD1) gene cause familial amyotrophic lateral sclerosis (ALS), a progressive fatal neuromuscular disease characterized by motor neurons death and severe skeletal muscle degeneration. However, there is no effective treatment for this debilitating disease, since the underlying cause for the pathogenesis remains poorly understood. Here, we investigated a role of acyl-CoA:lysocardiolipin acyltransferase 1 (ALCAT1), an acyltransferase that promotes mitochondrial dysfunction in age-related diseases by catalyzing pathological remodeling of cardiolipin, in promoting the development of ALS in the SOD1<sup>G93A</sup> transgenic mice.</AbstractText><AbstractText Label="METHODS">Using SOD1<sup>G93A</sup> transgenic mice with targeted deletion of the ALCAT1 gene and treated with Dafaglitapin (Dafa), a very potent and highly selective ALCAT1 inhibitor, we determined whether ablation or pharmaceutical inhibition of ALCAT1 by Dafa would mitigate ALS and the underlying pathogenesis by preventing pathological remodeling of cardiolipin, oxidative stress, and mitochondrial dysfunction by multiple approaches, including lifespan analysis, behavioral tests, morphological and functional analysis of skeletal muscle, electron microscopic and Seahorse analysis of mitochondrial morphology and respiration, western blot analysis of the SOD1<sup>G93A</sup> protein aggregation, and lipidomic analysis of cardiolipin content and acyl composition in mice spinal cord.</AbstractText><AbstractText Label="RESULTS">ALCAT1 protein expression is potently upregulated in the skeletal muscle of the SOD1<sup>G93A</sup> mice. Consequently, ablation or pharmacological inhibition of ALCAT1 by Dafa attenuates motor neuron dysfunction, neuronal inflammation, and skeletal muscle atrophy in SOD1<sup>G93A</sup> mice by preventing SOD1<sup>G93A</sup> protein aggregation, mitochondrial dysfunction, and pathological CL remodeling, leading to moderate extension of lifespan in the SOD1<sup>G93A</sup> transgenic mice.</AbstractText><AbstractText Label="CONCLUSIONS">ALCAT1 promotes the development of ALS by linking SOD1<sup>G93A</sup> protein aggregation to mitochondrial dysfunction, implicating Dafa as a potential treatment for this debilitating disorder.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xueling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China; Sam and Ann Barshop Institute for Longevity and Aging Studies, Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sam and Ann Barshop Institute for Longevity and Aging Studies, Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yuguang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China; Sam and Ann Barshop Institute for Longevity and Aging Studies, Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. Electronic address: shiy4@uthscsa.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055747</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Mol Metab</MedlineTA><NlmUniqueID>101605730</NlmUniqueID><ISSNLinking>2212-8778</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002308">Cardiolipins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.-</RegistryNumber><NameOfSubstance UI="D000217">Acyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.-</RegistryNumber><NameOfSubstance UI="C525544">lysocardiolipin acyltransferase, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000217" MajorTopicYN="Y">Acyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002308" MajorTopicYN="N">Cardiolipins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="Y">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Cardiolipin</Keyword><Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">Neuronal inflammation</Keyword><Keyword MajorTopicYN="N">SOD1 aggregation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35772643</ArticleId><ArticleId IdType="pmc">PMC9287437</ArticleId><ArticleId IdType="doi">10.1016/j.molmet.2022.101536</ArticleId><ArticleId IdType="pii">S2212-8778(22)00105-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shang H., Liu G., Jiang Y., Fu J., Zhang B., Song R., et al. Pathway analysis of two amyotrophic lateral sclerosis GWAS highlights shared genetic signals with Alzheimer's disease and Parkinson's disease. Molecular Neurobiology. 2015;51(1):361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">24647822</ArticleId></ArticleIdList></Reference><Reference><Citation>Walling A.D. Amyotrophic lateral sclerosis: Lou Gehrig's disease. American Family Physician. 1999;59(6):1489&#x2013;1496.</Citation><ArticleIdList><ArticleId IdType="pubmed">10193591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet Journal of Rare Diseases. 2009;4:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2017;16(7):505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A&#xa0;controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New England Journal of Medicine. 1994;330(9):585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine J.S., Doucette P.A., Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annual Review of Biochemistry. 2005;74:563&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">15952898</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins C.M., Jung C., Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neuroscience. 2003;4:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC169170</ArticleId><ArticleId IdType="pubmed">12864925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J., Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. Journal of Neuroscience. 1998;18(9):3241&#x2013;3250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792665</ArticleId><ArticleId IdType="pubmed">9547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Claypool S.M., Koehler C.M. The complexity of cardiolipin in health and disease. Trends in biochemical sciences. 2012;37(1):32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259273</ArticleId><ArticleId IdType="pubmed">22014644</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch G.M. Cell biology of cardiac mitochondrial phospholipids. Biochemistry and Cell Biology. 2004;82(1):99&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">15052331</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradies G., Paradies V., De Benedictis V., Ruggiero F.M., Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochimica et Biophysica Acta. 2014;1837(4):408&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">24183692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlame M., Rua D., Greenberg M.L. The biosynthesis and functional role of cardiolipin. Progress in Lipid Research. 2000;39(3):257&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799718</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y. Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases. J&#xa0;Biomed Res. 2010;24(1):6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596530</ArticleId><ArticleId IdType="pubmed">23554606</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Yang J., Cheng H., Yang K., Abendschein D.R., Gross R.W. Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry. 2005;44(50):16684&#x2013;16694.</Citation><ArticleIdList><ArticleId IdType="pubmed">16342958</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Yang J., Yang K., Zhao Z., Abendschein D.R., Gross R.W. Alterations in myocardial cardiolipin content and composition occur at the very earliest stages of diabetes: a shotgun lipidomics study. Biochemistry. 2007;46(21):6417&#x2013;6428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2139909</ArticleId><ArticleId IdType="pubmed">17487985</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia D., Zhang J., Nie J., Andersen J.P., Rendon S., Zheng Y., et al. Cardiolipin remodeling by ALCAT1 links hypoxia to coronary artery disease by promoting mitochondrial dysfunction. Molecular Therapy. 2021;29(12):3498&#x2013;3511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636157</ArticleId><ArticleId IdType="pubmed">34111561</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlame M., Towbin J.A., Heerdt P.M., Jehle R., DiMauro S., Blanck T.J. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Annals of Neurology. 2002;51(5):634&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparagna G.C., Chicco A.J., Murphy R.C., Bristow M.R., Johnson C.A., Rees M.L., et al. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. The Journal of Lipid Research. 2007;48(7):1559&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">17426348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu P., Shi Y. Regulation of autophagy by mitochondrial phospholipids in health and diseases. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2017;1862(1):114&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707390</ArticleId><ArticleId IdType="pubmed">27502688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu P., Liu X., Zhang J., Wang H.G., Ye J.M., Shi Y. Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy. Autophagy. 2015;11(4):643&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502692</ArticleId><ArticleId IdType="pubmed">25919711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Liu X., Nie J., Shi Y. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome. Autophagy. 2022:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">34985382</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Romestaing C., Han X., Li Y., Hao X., Wu Y., et al. Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity. Cell Metabolism. 2010;12(2):154&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923392</ArticleId><ArticleId IdType="pubmed">20674860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Ye B., Miller S., Yuan H., Zhang H., Tian L., et al. Ablation of ALCAT1 mitigates hypertrophic cardiomyopathy through effects on oxidative stress and mitophagy. Molecular and Cellular Biology. 2012;32(21):4493&#x2013;4504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486149</ArticleId><ArticleId IdType="pubmed">22949503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Liu X., Nie J., Zhang J., Kimball S.R., Zhang H., et al. ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis. Hepatology. 2015;61(2):486&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303512</ArticleId><ArticleId IdType="pubmed">25203315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyurina Y.Y., Polimova A.M., Maciel E., Tyurin V.A., Kapralova V.I., Winnica D.E., et al. LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: implication for mitochondrial dysfunction in Parkinson's disease. Free Radical Research. 2015;49(5):681&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430340</ArticleId><ArticleId IdType="pubmed">25740198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudioso A., Garcia-Rozas P., Casarejos M.J., Pastor O., Rodriguez-Navarro J.A. Lipidomic alterations in the mitochondria of aged parkin null mice relevant to autophagy. Frontiers in Neuroscience. 2019;13:329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491511</ArticleId><ArticleId IdType="pubmed">31068772</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C., Zhang J., Qi S., Liu Z., Zhang X., Zheng Y., et al. Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson's diseases. Aging Cell. 2019;18(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6516155</ArticleId><ArticleId IdType="pubmed">30838774</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves-Filho A.B., Pinto I.F.D., Dantas L.S., Xavier A.M., Inague A., Faria R.L., et al. Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Scientific Reports. 2019;9(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6691112</ArticleId><ArticleId IdType="pubmed">31406145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkinezos I.G., Bacman S.R., Hernandez D., Oca-Cossio J., Arias L.J., Perez-Pinzon M.A., et al. Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. Journal of Neuroscience. 2005;25(1):164&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725219</ArticleId><ArticleId IdType="pubmed">15634778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzo F., Mirra A., Carri M.T. Oxidative stress and mitochondrial damage in the pathogenesis of ALS: new perspectives. Neuroscience Letters. 2017;636:3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27150074</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Liu Y., Lockwood J., Burn P., Shi Y. A&#xa0;novel cardiolipin-remodeling pathway revealed by a gene encoding an endoplasmic reticulum-associated acyl-CoA:lysocardiolipin acyltransferase (ALCAT1) in mouse. Journal of Biological Chemistry. 2004;279(30):31727&#x2013;31734.</Citation><ArticleIdList><ArticleId IdType="pubmed">15152008</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi A.U., Saw N.L., Vogel H., Cunnigham A.D., Shamloo M., Mochly-Rosen D. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Molecular Medicine. 2018;10(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840540</ArticleId><ArticleId IdType="pubmed">29335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Osto C., Benador I.Y., Ngo J., Liesa M., Stiles L., Acin-Perez R., et al. Measuring mitochondrial respiration in previously frozen biological samples. Current Protocols in Cell Biology. 2020;89(1):e116.</Citation><ArticleIdList><ArticleId IdType="pubmed">33320426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhang J., Sun H., Liu X., Zheng Y., Xu D., et al. Defective phosphatidylglycerol remodeling causes hepatopathy, linking mitochondrial dysfunction to hepatosteatosis. Cell Mol Gastroenterol Hepatol. 2019;7(4):763&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463126</ArticleId><ArticleId IdType="pubmed">30831319</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Mu Y., Jiang Y., Song R., Yi J., Zhou J., et al. Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates. Cell Death &amp; Disease. 2018;9(3):407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5851998</ArticleId><ArticleId IdType="pubmed">29540819</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraj S., King A., Cleveland M., Pradat P.F., Corse A., Rothstein J.D., et al. Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study. Acta Neuropathol Commun. 2014;2:165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297389</ArticleId><ArticleId IdType="pubmed">25510661</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadeas S.T., Kraig S.E., O'Banion C., Lepore A.C., Maragakis N.J. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in&#xa0;vivo. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(43):17803&#x2013;17808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203804</ArticleId><ArticleId IdType="pubmed">21969586</ArticleId></ArticleIdList></Reference><Reference><Citation>Komine O., Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya Journal of Medical Science. 2015;77(4):537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664586</ArticleId><ArticleId IdType="pubmed">26663933</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D., Vaz A.R. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Frontiers in Cellular Neuroscience. 2014;8:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033073</ArticleId><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D., Rognoni F., van Duijn W., Verspaget H.W., Haasdijk E.D., Holstege J.C. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathologica. 2001;102(4):293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603803</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Lillo C., Jonsson P.A., Vande Velde C., Ward C.M., Miller T.M., et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron. 2004;43(1):5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15233913</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.N., Tjostheim S., Dasilva K., Taylor D., Zhao B., Rakhit R., et al. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. Journal of Neuroscience. 2012;32(26):8791&#x2013;8799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622344</ArticleId><ArticleId IdType="pubmed">22745481</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Y., Chattopadhyay M., Whitelegge J., Valentine J.S. SOD1 aggregation and ALS: role of metallation states and disulfide status. Current Topics in Medicinal Chemistry. 2012;12(22):2560&#x2013;2572.</Citation><ArticleIdList><ArticleId IdType="pubmed">23339308</ArticleId></ArticleIdList></Reference><Reference><Citation>Puttaparthi K., Wojcik C., Rajendran B., DeMartino G.N., Elliott J.L. Aggregate formation in the spinal cord of mutant SOD1 transgenic mice is reversible and mediated by proteasomes. Journal of Neurochemistry. 2003;87(4):851&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">14622116</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., O'Halloran T.V. Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. Journal of Biological Chemistry. 2005;280(17):17266&#x2013;17274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15691826</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao H., Anthonymuthu T.S., Kenny E.M., Amoscato A.A., Cole L.K., Hatch G.M., et al. Disentangling oxidation/hydrolysis reactions of brain mitochondrial cardiolipins in pathogenesis of traumatic injury. JCI insight. 2018;3(21)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6238757</ArticleId><ArticleId IdType="pubmed">30385716</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteiro-Cardoso V.F., Oliveira M.M., Melo T., Domingues M.R., Moreira P.I., Ferreiro E., et al. Cardiolipin profile changes are associated to the early synaptic mitochondrial dysfunction in Alzheimer's disease. Journal of Alzheimer's Disease. 2015;43(4):1375&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">25182746</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H., Mancuso D.J., Jiang X., Guan S., Yang J., Yang K., et al. Shotgun lipidomics reveals the temporally dependent, highly diversified cardiolipin profile in the mammalian brain: temporally coordinated postnatal diversification of cardiolipin molecular species with neuronal remodeling. Biochemistry. 2008;47(21):5869&#x2013;5880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2507872</ArticleId><ArticleId IdType="pubmed">18454555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281(5384):1851&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Liu J. Oxidation versus aggregation - how do SOD1 mutants cause ALS? Nature Medicine. 2000;6(12):1320&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100110</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson T.L., Corson L.B., Huang L., Burlingame A., Liu J., Bruijn L.I., et al. Toxicity of ALS-linked SOD1 mutants. Science. 2000;288(5465):399.</Citation><ArticleIdList><ArticleId IdType="pubmed">10798964</ArticleId></ArticleIdList></Reference><Reference><Citation>Agorogiannis E.I., Agorogiannis G.I., Papadimitriou A., Hadjigeorgiou G.M. Protein misfolding in neurodegenerative diseases. Neuropathology and Applied Neurobiology. 2004;30(3):215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15175075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokubo Y., Taniguchi A., Hasegawa M., Hayakawa Y., Morimoto S., Yoneda M., et al. alpha-Synuclein pathology in the amyotrophic lateral sclerosis/parkinsonism dementia complex in the Kii Peninsula, Japan. Journal of Neuropathology and Experimental Neurology. 2012;71(7):625&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710962</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M., Dykes-Hoberg M., Culotta V.C., Price D.L., Wong P.C., Rothstein J.D. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiology of Disease. 2001;8(6):933&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">11741389</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi M., D'Aurelio M., Gajewski C.D., Martushova K., Kiaei M., Beal M.F., et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. Journal of Biological Chemistry. 2002;277(33):29626&#x2013;29633.</Citation><ArticleIdList><ArticleId IdType="pubmed">12050154</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J., Hervias I., Henning M.S., Damiano M., Kawamata H., Manfredi G. Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities. Human Molecular Genetics. 2009;18(23):4552&#x2013;4564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773270</ArticleId><ArticleId IdType="pubmed">19779023</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J., Pan J., Mo J., Peng Y. MPO/HOCl facilitates apoptosis and ferroptosis in the SOD1(G93A) motor neuron of amyotrophic lateral sclerosis. Oxidative Medicine and Cellular Longevity. 2022;2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8845144</ArticleId><ArticleId IdType="pubmed">35178161</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. The Lancet Neurology. 2011;10(3):253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts K., Zeineddine R., Corcoran L., Li W., Campbell I.L., Yerbury J.J. Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype. Glia. 2013;61(3):409&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">23281114</ArticleId></ArticleIdList></Reference><Reference><Citation>Oono M., Okado-Matsumoto A., Shodai A., Ido A., Ohta Y., Abe K., et al. Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1. Journal of Neurochemistry. 2014;128(3):403&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">24032595</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller D.W., Cookson M.R., Dickson D.W. Glial cell inclusions and the pathogenesis of neurodegenerative diseases. Neuron Glia Biology. 2004;1(1):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435946</ArticleId><ArticleId IdType="pubmed">16614753</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Gutmann D.H., Roos R.P. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Human Molecular Genetics. 2011;20(2):286&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">20962037</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliandolo A., Giacoppo S., Bramanti P., Mazzon E. NLRP3 inflammasome activation in a transgenic amyotrophic lateral sclerosis model. Inflammation. 2018;41(1):93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">28936769</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Medicinal Research Reviews. 2019;39(2):733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Borras-Blasco J., Plaza-Macias I., Navarro-Ruiz A., Peris-Marti J., Anton-Cano A. [Riluzole as a treatment for amyotrophic lateral sclerosis] Revue Neurologique. 1998;27(160):1021&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">9951030</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>